BMO's Evan Seigerman expects US share losses to weigh on Ozempic sales, while the 25% CagriSema figure comes from a post-hoc subgroup, not the full trial's 22.7%.
Recap by typeshit. Full story at AD HOC NEWS.
Beauty companies are reportedly exploring products aimed at facial changes linked to rapid weight loss on GLP-1 drugs.
A search page for retatrutide news with no specific story attached, so there is little new beyond recent coverage.
2:06:48
A live Q&A stream from DOWNSIZED taking viewer questions about GLP-1 medications, including Zepbound, Wegovy and Foundayo.
A link to a betting market on whether Lilly's retatrutide gets FDA approval, with no reporting or detail on the drug's actual status.
Both suppliers of compounded semaglutide and tirzepatide ingredients landed on the FDA import-alert list. Times Now also covers dosing mistakes with compounded vials.
Bhekisisa reports illegal weight loss injections are still on sale, and the new rules meant to curb the trade are still months off.
Loading…